Bevacizumab and arterial hypertension or proteinuria: Management;Bevacizumab et hypertension artérielle ou protéinurie: Prise en charge

Revue des Maladies Respiratoires

Volumn 25, Issue 6, 2008, Pages 767-772

  Senellart, H ^a   Bennouna, J ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Arterial hypertension; Bevacizumab; Non small cell lung cancer; Proteinuria; Toxicities

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; DIURETIC AGENT; LERCANIDIPINE; LISINOPRIL; NEBIVOLOL; SORAFENIB; SUNITINIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

HUMAN; HYPERTENSION; PROTEINURIA; SHORT SURVEY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; INCIDENCE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; META ANALYSIS; PHASE 3 CLINICAL TRIAL; REVIEW; RISK; TIME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYPERTENSION; INCIDENCE; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; PROTEINURIA; RISK; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55249083942     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(08)73804-X     Document Type: Article

References (6)

1. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH : Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 ; 355 : 2542-50. Erratum in : N Engl J Med. 2007 ; 356 : 318.
2. Manegold C, Von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Reck M ; the BO17704 study group : Randomised, double-blind multicentrephase III study of bevacizumab in combination with cisplatine and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer. J Clin Oncol 2007 ; 18S : Abst 7514.
3. Zhu X, Wu S, Dahut WL, Parikh CR : Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor : systematic review and meta-analysis. Am J Kidney Dis 2007 ; 49 : 186-93.
4. Bennouna J, Von Pawel J, Zatloukal, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Moore N, Manegold C : Management of hypertension in patients with advanced or recurrent nonsquamous non-small cell lung cancer receiving first-line cisplatin and gemcitabine with bevacizumab or placebo-results from randomised phase III trial BO17704. Eur J Cancer 2007 ; 4S : Abst 6509.
5. Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn J, Dong W, Suzuki S, Sarkar S, Sugrue MM, Grothey A : Management of hypertension in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy. J Clin Oncol 2007 ; Gastrointestinal Cancers Symposium : Abst 364.
6. Siddiqui AJ, Mansson-BrobergA, Gustafsson T, Grinnema KH, Dellgren G, Hao X, Fischer H, Sylven C : Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens. 2005 ; 18 : 1347-52.